Prostate-specific membrane antigen (PSMA) is a transmembrane protein physiologically expressed in nonprostatic tissues. Inflammation and infectious diseases could show false-positive PSMA uptake. Herein, we present a 55-year-old patient's findings of inflammation in the lower respiratory tract due to inhaler use in 68 Ga-PSMA PET/CT in a patient with prostate cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000005015DOI Listing

Publication Analysis

Top Keywords

ga-psma pet/ct
8
lower respiratory
8
respiratory tract
8
pet/ct lower
4
tract inflammation
4
inflammation inhaler
4
inhaler prostate-specific
4
prostate-specific membrane
4
membrane antigen
4
antigen psma
4

Similar Publications

False Lymph Node Recurrence Image in PET/CT with [68Ga]Ga-PSMA-11. Importance of the Acquisition Protocol.

Rev Esp Med Nucl Imagen Mol (Engl Ed)

December 2024

Servicio de Medicina Nuclear, Hospital Clínic Barcelona, Barcelona, Spain; Universitat de Barcelona, Facultad de Medicina, Barcelona, Spain; Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

View Article and Find Full Text PDF

Ga-PSMA PET/CT-Based Model Predicts Perineural Invasion of Prostate Cancer with Whole-Mount Sections.

Mol Imaging Biol

December 2024

Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology Nanjing University, Jiangsu, China.

Purpose: To develop a novel risk model incorporating Ga-PSMA PET/CT parameters for prediction of perineural invasion (PNI) of prostate cancer (PCa).

Methods: The study retrospectively enrolled 192 PCa patients with preoperative multiparametric MRI, Ga-PSMA PET/CT and radical specimen. Imaging parameters were derived from both mpMRI and PET/CT images.

View Article and Find Full Text PDF

 This article evaluates whether parameters derived from the gallium-68-labeled prostate-specific membrane antigen ( Ga-PSMA) positron emission tomography/computed tomography (PET/CT) imaging studies of primary prostate cancer (PCa) lesions were associated with Gleason score (GS), D'Amico risk class, Candiolo nomograms, and the metastatic status of the disease.  We retrospectively evaluated newly diagnosed PCa patients who underwent Ga-PSMA PET/CT before therapy. Age, baseline serum prostate-specific antigen (PSA), and metastatic status were recorded.

View Article and Find Full Text PDF

Prostate cancer involving visceral organs are occurrences in the later disease course, usually following regional nodal and skeletal involvement, and are refractory to conventional treatment. A 61-year-old male patient presented with locally advanced disease at presentation, which progressed on androgen deprivation therapy and systemic therapy with involvement of the visceral organs (lungs and liver). Portal venous tumor thrombosis involving the right and main branch was also observed on contrast-enhanced computed tomography (CECT) and magnetic resonance imaging (MRI), which showed intense uptake on Ga-labeled prostate-specific membrane antigen positron emission tomography/computed tomography ( Ga-PSMA-11 PET/CT) and F-fluorodeoxyglucose PET/CT ( F-FDG-PET/CT).

View Article and Find Full Text PDF

Background: The NOTI chelating scaffold can readily be derivatized for bioconjugation without impacting its metal complexation/radiolabeling properties making it an attractive building block for the development of multimeric/-valent radiopharmaceuticals. The objective of the study was to further explore the potential of the NOTI chelating platform by preparing and characterizing homotrimeric PSMA radioconjugates in order to identify a suitable candidate for clinical translation.

Results: Altogether, three PSMA conjugates based on the NOTI-TVA scaffold with different spacer entities between the chelating unit and the Glu-CO-Lys PSMA binding motif were readily prepared by solid phase-peptide chemistry.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!